SEC EDGARJUL 12 min read$TBPH

Samaha Eli sold $5.8M of TBPH (indirect holdings)

Samaha Eli sold 336,697 indirectly-held shares of Theravance Biopharma, Inc. (TBPH) at an average of $17.20 ($17.00–$17.23, $5.79M total) across 3 trades over 2026-06-29 to 2026-07-01.

Original reporting

SEC EDGAR · Samaha Eli

Published Jul 1, 2026, 11:33 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Jul 1, 2026, 11:35 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$TBPH

Neutral

medium confidence

Mentioned

$TBPH

Relevance

6/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$TBPHNeutralLow

Why it matters

The newest concrete fact is the disclosed open-market sale size, price range, and post-transaction holdings; it may influence short-term sentiment but does not change fundamentals in the text.

Market read

Traders may reassess near-term sentiment around TBPH given a large owner’s disclosed sale, but there is no accompanying operational catalyst.

What to watch

The transaction is described as indirect holdings and explicitly notes no pre-arranged 10b5-1 plan, which can increase interpretive uncertainty for traders.

Relevance 6/10Novelty 6/10Timing: after-hours/filing date (2026-07-01) for late-June/early-July insider sale window

Background

The article is an SEC Form 4 insider transaction disclosure for Theravance Biopharma, Inc. (TBPH).

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$TBPHNeutralMedium confidence

Context

SEC Form 4 shows 10% owner Samaha Eli sold $5.79M of Theravance Biopharma shares via open-market sales (336,697 shares) in late June/early July.

Expected impact

Likely limited/short-lived impact; watch for follow-through selling or stabilization after the disclosed sale window.

Evidence & confidence

The filing is a primary-source insider transaction with clear size and timing, but it provides no new business, guidance, or regulatory/clinical catalyst.

Market effects

Sector

Biopharma insider-sale prints can slightly influence sentiment across small/mid-cap names, but this is company-specific and not sector-wide.

Regional

No direct regional spillover indicated; US-listed issuer filing only.

Global

Limited global relevance; no deal, trial, or regulatory action described.

Counterpoint

What could challenge this read

A sale can be routine liquidity/portfolio rebalancing and does not necessarily signal reduced confidence, especially without a 10b5-1 plan.

Key entities

issuer
Theravance Biopharma, Inc.
Subject of the Form 4 insider transaction; 10% owner sold shares totaling ~$5.79M.
insider
Samaha Eli
Reporter/10% owner who executed open-market sales (indirect holdings) between 2026-06-29 and 2026-07-01.

Read at source ← All news

SEP 28

$ZYMEHigh

Zymeworks (ZYME) Completes Theravance Biopharma Acquisition, Int

Zymeworks (ZYME) completed its acquisition of Theravance Biopharma, adding the respiratory drug YUPELRI to its portfolio. The move aims to provide steady revenue and support growth. Zymeworks trades at a high P/S ratio of 53.9, reflecting growth expectations, but remains unprofitable. Its GF Score is 61, indicating moderate fundamental health with strengths in valuation and momentum but weaknesses in profitability and growth.

gurufocus.com3 min

SEP 23

$ZYMEHighAI 8/10

Zymeworks Inc.: Zymeworks Completes Acquisition of Theravance Biopharma

Zymeworks Inc. (ZYME) completed its acquisition of Theravance Biopharma, integrating the company to diversify its revenue streams. Zymeworks will host a conference call on September 28 to discuss the transaction details. The acquisition aims to advance Zymeworks' strategy of combining innovative R&D with commercial and royalty-based cash flows.

finanznachrichten.de2 min

SEP 23

$TBPHHigh

Theravance Biopharma, Inc. (TBPH): Completion of Acquisition or Disposition of Assets

Theravance Biopharma, Inc. (TBPH) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of September 22, 2026 (this “ Agreement ”), is entered into by and between Zymeworks Inc., a Delaware corporation (“ Parent ”), and Computershare Inc., a Delaware corporation (“ Comput

SEC EDGAR 8-K2 min

AUG 10

$TBPHMedAI 8/10

Theravance Biopharma Q2 2026: Viatris collaboration revenue $20.7M; net loss $5.9M; $388M cash

Theravance Biopharma reported Q2 2026 revenue of $20.7M, all from its Viatris collaboration, up 11% YoY. GAAP net loss was $5.9M. Cash and marketable securities were $387.7M at June 30, 2026. The company said a Zymeworks acquisition is expected to close in H2 2026, and it cited restructuring cost savings.

tradingview.com2 min

AUG 10

$TBPHHigh

Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Theravance Biopharma, Inc. (TBPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update · Previously announced acquisition by Zymeworks expected to close in second half of 2026 · YUPELRI ® Collaboration Revenue increased 11% year-over-year 1 , from $18

SEC EDGAR 8-K6 min

JUL 21

$ZYMEHighAI 9/10

USA: Zymeworks acquisisce Theravance Biopharma, focus su YUPELRI per diversificare il portafoglio e accelerare la crescita – Padovanews

Zymeworks Inc. agreed to acquire Theravance Biopharma, adding YUPELRI (revefenacin) for COPD. The deal values Theravance at $17/share, with a $350 million non-recourse note and $219 million cash plus Theravance’s estimated $360 million net cash at closing. YUPELRI U.S. net sales were $266.6M in 2025. Expected close in H2 2026.

padovanews.it5 min